Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL5022406 | 0.88 | TSHR (0.43) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL11451456 | 0.85 | TSHR (0.45) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL11008253 | 0.84 | TSHR (0.42) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL3102870 | 0.83 | TSHR (0.46) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL6290785 | 0.82 | TSHR (0.45) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL20578185 | 0.82 | TSHR (0.45) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL29101198 | 0.81 | TSHR (0.45) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL4883991 | 0.81 | TSHR (0.49) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL1759450 | 0.81 | TSHR (0.47) | TSHRCYP3A4TDP1ATMCA2 | |
| SCHEMBL21496176 | 0.81 | TSHR (0.44) | TSHRCYP3A4TDP1ATMCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149439-B2 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2015-10-06 | — | — | US | claimed |
| US-8168228-B2 | Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix | SANDOZ AG (CH) | 2012-05-01 | — | — | US | claimed |
| US-7607596-B1 | Process for enhancing the solubility of poorly soluble drugs | Exxpharma, LLC (US) | 2009-10-27 | — | — | US | claimed |
| US-20090060848-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | JOSHI YATINDRA | 2009-03-05 | — | — | US | claimed |
| EP-1680088-B1 | Taste-masked formulation comprising clarithromycin | SANDOZ AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20070148247-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA | 2007-06-28 | — | — | US | claimed |
| US-20070134344-A1 | Antibiotic compositions | SANDOZ AG (CH) | 2007-06-14 | — | — | US | claimed |
| US-20070048379-A1 | Valproate tablet | GUO MINTONG | 2007-03-01 | — | — | US | claimed |
| WO-2006102446-A2 | MULTI-PARTICULATE, MODIFIED-RELEASED COLONIC COMPOSITION | SANDOZ AG (CH) | 2006-09-28 | — | — | WO | claimed |
| US-20060210631-A1 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2006-09-21 | — | — | US | claimed |
| EP-1680088-A1 | ANTIBIOTIC COMPOSITIONS | Sandoz AG (CH) | 2006-07-19 | — | — | EP | claimed |
| WO-2005077342-A1 | ENTERICALLY COATED LANSOPRAZOLE MICROTABLETS | SANDOZ AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-20050181052-A1 | Lansoprazole microtablets | PATEL SATISHKUMAR A (US) | 2005-08-18 | — | — | US | claimed |
| WO-2005039536-A1 | ANTIBIOTIC COMPOSITIONS | SANDOZ AG (CH) | 2005-05-06 | — | — | WO | claimed |
| US-20050084541-A1 | Antibiotic compositions | SANDOZ, AG (CH) | 2005-04-21 | — | — | US | claimed |
| US-20050084540-A1 | Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix | SANDOZ INC. | 2005-04-21 | — | — | US | claimed |
| US-20040042964-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2004-03-04 | — | — | US | claimed |
| US-20020187192-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2002-12-12 | — | — | US | claimed |
| WO-2002087558-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | NOVARTIS AG (CH) | 2002-11-07 | — | — | WO | claimed |
| US-20240238205-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240216372-A1 | THERAPEUTICS FOR KELOIDS AND OTHER FIBROTIC DISORDERS | NATIONAL INSTITUTES OF HEALTH | 2024-07-04 | — | — | US | disclosed |
| US-20240207359-A1 | INHIBITION OF BETA-ARRESTIN OLIGOMERIZATION IN TAUOPATHY | UNIVERSITY OF SOUTH FLORIDA | 2024-06-27 | — | — | US | disclosed |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387626-A1 | ALLOPREGNANOLONE ANALOGUES FOR HIV VIREMIA AND NEUROTOXICITY PROTECTION | University of Mississippi (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3793562-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024123639-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | THE UAB RESEARCH FOUNDATION (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240180221-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE LTD (SG) | 2024-06-06 | — | — | US | disclosed |
| US-20240182471-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-06-06 | — | — | US | disclosed |
| US-11999697-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240165030-A1 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-23 | — | — | US | disclosed |
| WO-2024102999-A2 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS INFECTIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102890-A2 | AMINO ACID-BENZOIC ACID OLIGOMERS AND METHODS OF USE THEREOF FOR TREATING CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240156802-A1 | METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| US-20240156788-A1 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | NORTH CAROLINA STATE UNIVERSITY | 2024-05-16 | — | — | US | disclosed |
| EP-4366720-A1 | THE USE OF BETA-HYDROXYBUTYRATES FOR THE TREATMENT OR PREVENTION OF ANEURYSMS AND DISSECTIONS | Georgia State University Research Foundation, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11980690-B2 | Centanafadine pharmaceutical formulations, and methods of making and using same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-14 | — | — | US | disclosed |
| EP-4363411-A1 | CANNABICHROMENE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME | University of Mississippi (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4362968-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4363398-A1 | COMPOUNDS AND METHODS FOR DEGRADING RCOR1, LSD1, HDAC1 AND HDAC2 IN THE COREST | University of Florida Research Foundation, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240140912-A1 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH | 2024-05-02 | — | — | US | disclosed |
| US-20240132463-A1 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024081789-A2 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4351731-A2 | GENETICALLY-MODIFIED SACCHAROMYCES YEAST STRAINS AS PREVENTATIVE AND THERAPEUTIC AGENTS | Fzata, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11957682-B2 | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-04-16 | — | — | US | disclosed |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | AKIRABIO, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11938105-B1 | Methods and compositions for the treatment of cancer cachexia | OHIO STATE INNOVATION FOUNDATION (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2024059668-A2 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024048782-A1 | 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-07 | — | — | WO | disclosed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11912704-B2 | Methods and compositions for substituted arylcycloheptane analogs | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11896644-B2 | Inhibition of beta-arrestin oligomerization in tauopathy | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4312587-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | Almendra Pte. Ltd. (SG) | 2024-02-07 | — | — | EP | disclosed |
| US-11890378-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2024026359-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PARASITIC WORMS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11883384-B2 | Substituted 2-aminobenzimidazoles analogs as antibiofilm agents | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240018108-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2024015618-A2 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4297734-A1 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-01-03 | — | — | EP | disclosed |
| EP-4297732-A1 | METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4284775-A2 | A NEW MOLECULAR SCAFFOLD FOR TARGETING HRPN13 | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| WO-2023230500-A1 | SPLEEN TYROSINE KINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230365521-A1 | COMPOUNDS FOR INCREASING THE NICOTINAMIDE ADENINE DINUCLEOTIDE IN A SUBJECT AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| US-20230338293-A1 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2023205764-A1 | OPIOID RECEPTOR AGONIST AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023196952-A2 | METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230310461-A1 | Compositions and Methods for Treatment of Prediabetes | CROSS III WILLIAM H (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023192921-A2 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303581-A1 | ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS | UNIV MISSISSIPPI (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
| US-11759426-B2 | Centanafadine pharmaceutical formulations, and methods of making and using same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-11759450-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285442-A1 | USE OF OLIGOCHITOSANS AND DERIVATIVES THEREOF FOR NEUTRALIZING VIRAL AGENTS | MOHAPATRA SUBHRA (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4228623-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Ohio State Innovation Foundation (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | ADIMABIO LLC (US) | 2023-08-10 | — | — | US | disclosed |
| WO-2023150534-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023147571-A2 | SELECTIVE AGENTS TARGETING MYCOBACTERIUM TUBERCULOSIS | UNIVERSITY OF MISSISSIPPI (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4217352-A1 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | St. Jude Children's Research Hospital, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023108036-A1 | CANNABINOID RECEPTOR MODULATING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230181470-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230181746-A1 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2022125913-A9 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023096995-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED N-(2-CHLORO-6-METHYLPHENYL)-2-((6-(6-MEMBERED HETEROCYCLOALKYL)-2-METHYLPYRIMIDIN-4-YL)AMINO)THIAZOLE-5-CARBOXAMIDE ANALOGUES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096822-A1 | SUBSTITUTED 2-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)ACETAMIDE ANALOGS AS MODULATORS OF GSPT1 AND/OR IKZF1 PROTEIN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230158030-A1 | METHODS AND COMPOSITION FOR TREATMENT OF COVID-19 ILLNESS REQUIRING HOSPITALIZATION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4181912-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN | Schabar Research Associates LLC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11655468-B2 | Methods and compositions of chemically modified phage libraries | THE TRUSTEES OF BOSTON COLLEGE (MA) | 2023-05-23 | — | — | US | disclosed |
| WO-2023087012-A1 | METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230149338-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023081224-A1 | SUBSTITUTED N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4- YL)METHYL)BENZAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230138583-A1 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | OHIO STATE INNOVATION FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| WO-2023069529-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230124492-A1 | COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE ANALOGS AS INHIBITORS OF KRAS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | CUSTOMERS BANK | 2023-04-20 | — | — | US | disclosed |
| US-20230123277-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA | AKIRABIO INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230116783-A1 | INHIBITION OF BETA-ARRESTIN OLIGOMERIZATION IN TAUOPATHY | NATIONAL INSTITUTES OF HEALTH | 2023-04-13 | — | — | US | disclosed |
| US-20230109418-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230104529-A1 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| US-20230103257-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3 | OHIO STATE INNOVATION FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| EP-4153160-A1 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | University of Florida Research Foundation (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230089605-A1 | USE OF DOXYCYCLINE, RESVERATROL, IVERMECTIN, AND RELATED CHEMICALLY MODIFIED COMPOUNDS TO TREAT OR PREVENT VIRAL INFECTIONS | Ardestat Biologics, LLC | 2023-03-23 | — | — | US | disclosed |
| US-20230089524-A1 | COMPOSITIONS FOR USE IN THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC | 2023-02-23 | — | — | US | disclosed |
| WO-2023023650-A1 | ALLOPREGNANOLONE ANALOGUES FOR HIV VIREMIA AND NEUROTOXICITY PROTECTION | UNIVERSITY OF MISSISSIPPI (US) | 2023-02-23 | — | — | WO | disclosed |
| US-11576871-B2 | Formulations of cysteamine and cystamine | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-14 | — | — | US | disclosed |
| US-11564885-B2 | Centanafadine pharmaceutical formulations, and methods of making and using same | OTSUKA PHARMACEUTICAL CO, LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230018590-A1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-01-19 | — | — | US | disclosed |
| WO-2023283654-A1 | THE USE OF BETA-HYDROXYBUTYRATES FOR THE TREATMENT OR PREVENTION OF ANEURYSMS AND DISSECTIONS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023278719-A1 | CANNABICHROMENE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME | UNIVERSITY OF MISSISSIPPI (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278778-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278977-A1 | COMPOUNDS AND METHODS FOR DEGRADING RCOR1, LSD1, HDAC1 AND HDAC2 IN THE COREST | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-11529323-B2 | Methods and compositions for the treatment of cancer cachexia | OHIO STATE INNOVATION FOUNDATION (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022261455-A2 | GENETICALLY-MODIFIED SACCHAROMYCES YEAST STRAINS AS PREVENTATIVE AND THERAPEUTIC AGENTS | FZATA, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4100023-A1 | INHIBITION OF BETA-ARRESTIN OLIGOMERIZATION IN TAUOPATHY | University of South Florida (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4081219-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11471413-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220322709-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE LTD (SG) | 2022-10-13 | — | — | US | disclosed |
| WO-2022216961-A1 | NAMPT ACTIVATORS FOR TREATING METABOLIC AND NEUROLOGICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022208443-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE. LTD. (SG) | 2022-10-06 | — | — | WO | disclosed |
| EP-4061808-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| US-20220274948-A1 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | CYRUS THERAPEUTICS, INC. (KR) | 2022-09-01 | — | — | US | disclosed |
| US-20220233509-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF NAPROXEN SODIUM AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN | SCHABAR RESEARCH ASSOCIATES LLC | 2022-07-28 | — | — | US | disclosed |
| US-20220233510-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN | SCHABAR RESEARCH ASSOCIATES LLC | 2022-07-28 | — | — | US | disclosed |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213055-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| US-11369608-B2 | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-4010326-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Ohio State Innovation Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20220177457-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| WO-2022104108-A1 | METHODS AND COMPOSITIONS FOR CANCER THERAPY | OHIO STATE INNOVATION FOUNDATION (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220151933-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2022-05-19 | — | — | US | disclosed |
| US-11331307-B2 | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn | SCHABAR RESEARCH ASSOCIATES, LLC (US) | 2022-05-17 | — | — | US | disclosed |
| US-11324727-B2 | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn | SCHABAR RESEARCH ASSOCIATES, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11312686-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | OHIO STATE INNOVATION FOUNDATION (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022081552-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OHIO STATE INNOVATION FOUNDATION (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022066835-A1 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3962485-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | University Of Virginia Patent Foundation (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220064119-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | HENDRIX COLLEGE | 2022-03-03 | — | — | US | disclosed |
| US-20220062230-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | UNIV ILLINOIS (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220016088-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN | SCHABAR RESEARCH ASSOCIATES LLC | 2022-01-20 | — | — | US | disclosed |
| US-20220016087-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF NAPROXEN SODIUM AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY OF HEARTBURN AND/OR THE RISK OF HEARTBURN | SCHABAR RESEARCH ASSOCIATES LLC | 2022-01-20 | — | — | US | disclosed |
| WO-2022015784-A1 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN | SCHABAR RESEARCH ASSOCIATES LLC (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022015974-A2 | SUBSTITUTED 4-(3-AMINOPROP-1-YL)AMINOQUINOLINE ANALOGS AS MODULATORS OF MELANOMA-ASSOCIATED ANTIGEN 11 UBIQUITIN LIGASE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-3937926-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | St. Jude Children's Research Hospital, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939574-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION | Horizon Orphan LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210401845-A1 | METHODS AND COMPOSITIONS FOR KRAS INHIBITORS | UNIV TEXAS (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210388012-A1 | METHODS AND COMPOSITIONS FOR PRODRUG FORMS OF SPECTINOMYCIN AND SPECTINAMIDE ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-16 | — | — | US | disclosed |
| WO-2021236491-A1 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20210332107-A1 | MODIFIED SERINE PROTEINASE INHIBITORS AND APPLICATIONS THEREOF | IONIC BIOMEDICAL INCORPORATED (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2021211890-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211540-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-21 | — | — | WO | disclosed |
| US-11141418-B1 | Methods and compositions for KRAS inhibitors | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210300928-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021195452-A1 | USE OF OLIGOCHITOSANS AND DERIVATIVES THEREOF FOR NEUTRALIZING VIRAL AGENTS | MOHAPATRA SUBHRA (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210253531-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION | 2021-08-19 | — | — | US | disclosed |
| US-11090279-B2 | Delayed release cysteamine bead formulation, and methods of making and using same | HORIZON ORPHAN LLC (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2021159093-A1 | INHIBITION OF BETA-ARRESTIN OLIGOMERIZATION IN TAUOPATHY | UNIVERSITY OF SOUTH FLORIDA (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3856182-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210198657-A1 | METHODS AND COMPOSITIONS OF CHEMICALLY MODIFIED PHAGE LIBRARIES | THE TRUSTEES OF BOSTON COLLEGE (US) | 2021-07-01 | — | — | US | disclosed |
| WO-2021133831-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133833-A1 | COMPOSITIONS FOR USE IN THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021134045-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021134042-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210177762-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2021-06-17 | — | — | US | disclosed |
| WO-2021119343-A1 | COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE ANALOGS AS INHIBITORS OF KRAS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021101875-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210154146-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-20210145804-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2021-05-20 | — | — | US | disclosed |
| EP-3793562-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | Ohio State Innovation Foundation (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2021050672-A1 | KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OHIO STATE INNOVATION FOUNDATION (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210062171-A1 | NOVEL SIALIDASES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-04 | — | — | US | disclosed |
| US-10933020-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10925832-B2 | Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3774740-A2 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | Ohio State Innovation Foundation (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210030770-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | UNIV SOUTH FLORIDA (US) | 2021-02-04 | — | — | US | disclosed |
| US-10905662-B2 | Methods for storing cysteamine formulations and related methods of treatment | HORIZON ORPHAN LLC (US) | 2021-02-02 | — | — | US | disclosed |
| US-20210023060-A1 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | NORTH CAROLINA STATE UNIVERSITY | 2021-01-28 | — | — | US | disclosed |
| WO-2020257733-A1 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3749654-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | The Board of Trustees of the University of Illinois (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10828312-B2 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders | UNIVERSITY OF SOUTH FLORIDA | 2020-11-10 | — | — | US | disclosed |
| WO-2020223715-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200339525-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3 | OHIO STATE INNOVATION FOUNDATION | 2020-10-29 | — | — | US | disclosed |
| US-20200316063-A1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | UNIVERSITY OF VIRGINIA | 2020-10-08 | — | — | US | disclosed |
| EP-3710001-A1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | University Of Virginia Patent Foundation (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200289438-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | OHIO STATE INNOVATION FOUNDATION | 2020-09-17 | — | — | US | disclosed |
| US-20200289419-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020186110-A1 | SMALL MOLECULES THAT BIND CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27KIP1) | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200261381-A1 | METHODS FOR STORING CYSTEAMINE FORMULATIONS AND RELATED METHODS OF TREATMENT | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2020-08-20 | — | — | US | disclosed |
| EP-3687514-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3 | Ohio State Innovation Foundation (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3681493-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | The Ohio State Innovation Foundation (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200129527-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-04-30 | — | — | US | disclosed |
| US-20200101018-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2020-04-02 | — | — | US | disclosed |
| US-20200101022-A1 | FORMULATIONS OF CYSTEAMINE AND CYSTAMINE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-02 | — | — | US | disclosed |
| WO-2020069301-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020033567-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2020-02-13 | — | — | WO | disclosed |
| US-10548859-B2 | Methods for storing Cysteamine formulations and related methods of treatment | HORIZON ORPHAN LLC (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2020023620-A1 | METHODS AND COMPOSITIONS OF CHEMICALLY MODIFIED PHAGE LIBRARIES | TRUSTEES OF BOSTON COLLEGE (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019195493-A2 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190298665-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2019-10-03 | — | — | US | disclosed |
| WO-2019157020-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-15 | — | — | WO | disclosed |
| US-10328037-B2 | Methods for storing cysteamine formulations and related methods of treatment | HORIZON ORPHAN LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190111008-A1 | METHODS FOR STORING CYSTEAMINE FORMULATIONS AND RELATED METHODS OF TREATMENT | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2019067696-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3 | OHIO STATE INNOVATION FOUNDATION (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019055687-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | OHIO STATE INNOVATION FOUNDATION (US) | 2019-03-21 | — | — | WO | disclosed |
| US-10143665-B2 | Methods for storing cysteamine formulations and related methods of treatment | HORIZON ORPHAN LLC (US) | 2018-12-04 | — | — | US | disclosed |
| US-10064817-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2018-09-04 | — | — | US | disclosed |
| WO-2018093364-A1 | FORMULATIONS OF CYSTEAMINE AND CYSTAMINE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-24 | — | — | WO | disclosed |
| US-9919050-B2 | Compositions comprising azelastine | MEDA PHARMACEUTICALS INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9872859-B2 | Materials and methods for targeting therapeutic compositions to gut-associated lymphoid tissue (GALT) | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170319513-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME | HORIZON ORPHAN LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319512-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME | HORIZON ORPHAN LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319514-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME | HORIZON ORPHAN LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170239258-A1 | MATERIALS AND METHODS FOR TARGETING THERAPEUTIC COMPOSITIONS TO GUT-ASSOCIATED LYMPHOID TISSUE (GALT) | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170135968-A1 | Methods for Storing Cysteamine Formulations and Related Methods of Treatment | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2017-05-18 | — | — | US | disclosed |
| US-20160331704-A1 | Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same | HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA RAPTOR PHARMACEUTICALS INC.) | 2016-11-17 | — | — | US | disclosed |
| EP-2377557-B1 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160158170-A1 | Delayed Release Cysteamine Bead Formulation, And Methods Of Making And Using Same | HORIZON ORPHAN LLC | 2016-06-09 | — | — | US | disclosed |
| EP-3010491-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION | Raptor Pharmaceuticals Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160095827-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION, AND METHODS OF MAKING AND USING SAME | HORIZON ORPHAN LLC | 2016-04-07 | — | — | US | disclosed |
| US-9233077-B2 | Delayed release cysteamine bead formulation, and methods of making and using same | RAPTOR PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9173851-B1 | Delayed release cysteamine bead formulation, and methods of making and using same | RAPTOR PHARMACEUTICALS INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150290139-A1 | Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2015-10-15 | — | — | US | disclosed |
| US-9149439-B2 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9138430-B2 | Formulation and method for the release of paroxetine in the large intestine | MYLAN SPECIALTY L.P. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9056134-B2 | Single daily dosage form for prevention and treatment of metabolic syndrome | NUCITEC S.A. DE C.V. (MX) | 2015-06-16 | — | — | US | disclosed |
| WO-2014204881-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION | RAPTOR PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20140370085-A1 | Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2014-12-18 | — | — | US | disclosed |
| US-8895061-B2 | Compositions comprising carisoprodol and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8846115-B2 | Anti-inflammatory cyclooxygenase inhibitors | METAPROTEOMICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8758816-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140158117-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140066520-A1 | NOVEL ANTI-INFLAMMATORY CYCLOOXYGENASE INHIBITORS | METAPROTEOMICS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8609154-B2 | Anti-inflammatory cyclooxygenase inhibitors | METAPROTEOMICS, LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-8518919-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2522365-A1 | Compositions comprising azelastine and methods of use thereof | Meda Pharmaceuticals Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120270951-A1 | NOVEL ANTI-INFLAMMATORY CYCLOOXYGENASE INHIBITORS | FORTRESS CREDIT CORP. (AS COLLATERAL AGENT) | 2012-10-25 | — | — | US | disclosed |
| EP-2486942-A1 | COMPOSITIONS COMPRISING AZELASTINE AND METHODS OF USE THEREOF | Meda Pharmaceuticals Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120149690-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8168228-B2 | Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix | SANDOZ AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20120095059-A1 | Compositions and Methods for Treating Type II Diabetes and Related Disorders | ROSADO JORGE LUIS (MX) | 2012-04-19 | — | — | US | disclosed |
| US-8158160-B2 | Anti-inflammatory cyclooxygenase inhibitors | FORTRESS CREDIT CORP. (AS COLLATERAL AGENT) | 2012-04-17 | — | — | US | disclosed |
| US-20120083479-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2012010977-A2 | SINGLE DAILY DOSAGE FORM FOR PREVENTION AND TREATMENT OF METABOLIC SYNDROME | NUCITEC S.A. DE C.V. (MX) | 2012-01-26 | — | — | WO | disclosed |
| US-20120021049-A1 | Single Daily Dosage Form for Prevention and Treatment of Metabolic Syndrome | NUCITEC S.A. DE C.V. (MX) | 2012-01-26 | — | — | US | disclosed |
| EP-2377557-A2 | Compositions comprising azelastine and methods of use thereof | MedPointe Healthcare Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100189782-A1 | Compositions Comprising Carisoprodol and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100152147-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | MEDA PHARMACEUTICALS INC. | 2010-06-17 | — | — | US | disclosed |
| US-7607596-B1 | Process for enhancing the solubility of poorly soluble drugs | Exxpharma, LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090169616-A1 | FORMULATION AND METHOD FOR THE RELEASE OF PAROXETINE IN THE LARGE INTESTINE | MYLAN INC. | 2009-07-02 | — | — | US | disclosed |
| EP-1126828-B1 | ORAL ADMINISTRATION OF ADENOSINE ANALOGS | MAYNE PHARMA PLC (GB) | 2009-04-01 | — | — | EP | disclosed |
| US-20090060848-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | JOSHI YATINDRA | 2009-03-05 | — | — | US | disclosed |
| EP-1680088-B1 | Taste-masked formulation comprising clarithromycin | SANDOZ AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008109018-A1 | COMPOSITIONS COMPRISING CARISOPRODOL AND METHODS OF USE THEREOF | MEDA PHARMACEUTICALS INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080096831-A1 | Stabilized azithromycin composition | SADATREZAEI MOHSEN | 2008-04-24 | — | — | US | disclosed |
| EP-1827499-A1 | COMPOSITIONS COMPRISING AZELASTINE AND METHODS OF USE THEREOF | MedPointe Healthcare Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070148247-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA | 2007-06-28 | — | — | US | disclosed |
| US-20070134344-A1 | Antibiotic compositions | SANDOZ AG (CH) | 2007-06-14 | — | — | US | disclosed |
| WO-2007061454-A1 | COMPOSITIONS COMPRISING AZELASTINE AND METHODS OF USE THEREOF | MEDPOINTE HEALTHCARE INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070066517-A1 | Composition and method for treating graft-versus-host disease | DIMARTINO JORGE | 2007-03-22 | — | — | US | disclosed |
| US-20070048379-A1 | Valproate tablet | GUO MINTONG | 2007-03-01 | — | — | US | disclosed |
| US-7173016-B2 | Composition and method for treating graft-versus-host disease | MAYNE PHARMA (USA) INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070020330-A1 | Compositions comprising azelastine and methods of use thereof | MEDPOINTE HEALTHCARE INC. (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2006102446-A2 | MULTI-PARTICULATE, MODIFIED-RELEASED COLONIC COMPOSITION | SANDOZ AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060210631-A1 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2006-09-21 | — | — | US | disclosed |
| EP-1682562-A1 | A STABILIZED AZITHROMYCIN COMPOSITION | Sandoz AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| EP-1680088-A1 | ANTIBIOTIC COMPOSITIONS | Sandoz AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| EP-1443820-A4 | COMPOSITION AND METHOD FOR TREATING GRAFT-VERSUS-HOST DISEASE | SUPERGEN INC (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006058022-A1 | COMPOSITIONS COMPRISING AZELASTINE AND METHODS OF USE THEREOF | MEDPOINTE HEALTHCARE INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060110331-A1 | Compositions comprising azelastine and methods of use thereof | MEDPOINTE HEALTHCARE INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-7037900-B2 | Composition and method for treating graft-versus-host disease | SUPERGEN, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1646403-A2 | PHARMACEUTICAL COMPOSITION FOR SOLUBILITY ENHANCEMENT OF HYDROPHOBIC DRUGS | Sandoz AG (CH) | 2006-04-19 | — | — | EP | disclosed |
| US-7030154-B2 | Stability of lipoic acid | JUVENON, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060025359-A1 | Composition and method for treating graft-versus-host disease | MAYNE PHARMA (USA) INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050226923-A1 | Venlafaxine compositions in the form of microtablets | GASSERT CHAD M | 2005-10-13 | — | — | US | disclosed |
| WO-2005077342-A1 | ENTERICALLY COATED LANSOPRAZOLE MICROTABLETS | SANDOZ AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| US-20050181052-A1 | Lansoprazole microtablets | PATEL SATISHKUMAR A (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005044834-A1 | A STABILIZED AZITHROMYCIN COMPOSITION | SANDOZ AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101547-A1 | Stabilized azithromycin composition | SADATREZAEI MOHSEN (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005039536-A1 | ANTIBIOTIC COMPOSITIONS | SANDOZ AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050084541-A1 | Antibiotic compositions | SANDOZ, AG (CH) | 2005-04-21 | — | — | US | disclosed |
| US-20050084540-A1 | Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix | SANDOZ INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005004917-A2 | PHARMACEUTICAL COMPOSITION FOR SOLUBILITY ENHANCEMENT OF HYDROPHOBIC DRUGS | SANDOZ AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050008704-A1 | Pharmaceutical composition for solubility enhancement of hydrophobic drugs | RAY ANUP KUMAR (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1443820-A1 | COMPOSITION AND METHOD FOR TREATING GRAFT-VERSUS-HOST DISEASE | SuperGen, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040042964-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2004-03-04 | — | — | US | disclosed |
| US-20040044046-A1 | Mixture of nicotinamide | JUVENON, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6667058-B1 | Administering for analgesic therapy solid dosage form of flupirtine in which sedative side effects are largely or totally suppressed | VIATRIS GMBH & CO. KG (DE) | 2003-12-23 | — | — | US | disclosed |
| US-20030215506-A1 | Methods and compositions for enhancement of creatine transport | KUHRTS ERIC H (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030091656-A1 | Analgesics for osteoporosis, rheumatic diseases; side effect reduction; extract from hops | FORTRESS CREDIT CORP. (AS COLLATERAL AGENT) | 2003-05-15 | — | — | US | disclosed |
| US-20030073649-A1 | Composition and method for treating graft-versus-host disease | MAYNE PHARMA (USA) INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003030643-A1 | COMPOSITION AND METHOD FOR TREATING GRAFT-VERSUS-HOST DISEASE | SUPERGEN, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20020187192-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2002-12-12 | — | — | US | disclosed |
| WO-2002087558-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | NOVARTIS AG (CH) | 2002-11-07 | — | — | WO | disclosed |
| US-20020086070-A1 | Anti-inflammatory and connective tissue repair formulations | METAPROTEOMICS, INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020068365-A1 | CONTROLLED RELEASE NITRIC OXIDE PRODUCING AGENTS | KUHRTS ERIC H (US) | 2002-06-06 | — | — | US | disclosed |
| US-6387945-B2 | REACTING AN AMINE AND A CARBOXY-1,2-DITHIOLANE DERIVATIVE TO PRODUCE COMPOUNDS SUCH AS N,N-DIMETHYL-N-2-AMIDOETHYL LIPOATE USED TO TREAT CONDITIONS INVOLVING REACTIVE OXYGEN SPECIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-14 | — | — | US | disclosed |
| US-20010039292-A1 | Lipoic acid analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| EP-1126828-A1 | ORAL ADMINISTRATION OF ADENOSINE ANALOGS | SuperGen, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6271254-B1 | Pharmaceutical compositions containing R-α-lipoic acid or S-α-lipoic acid as active ingredient | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | disclosed |
| WO-2001035953-A2 | EXERCISE AND MUSCLE ENHANCEMENT FORMULATIONS | KUHRTS ERIC H (US) | 2001-05-25 | — | — | WO | disclosed |
| US-6235772-B1 | OXIDATION RESISTANCE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-05-22 | — | — | US | disclosed |
| US-6191162-B1 | ADMINISTERING LIPOIC ACID | MEDICAL RESEARCH INSTITUTE | 2001-02-20 | — | — | US | disclosed |
| US-6174873-B1 | ADMINISTERING BY MOUTH AN ACID-LABILE 2'-DEOXYADENOSINE ANALOG THAT IS ISOLATED FROM THE STOMACH ACID; PROTECTIVE COATINGS; ERODIBLE MATRIX, SOLID DISPERSION, AND ION EXCHANGE RESINT; ANTICARCINOGENIC,-TUMOR AGENTS | SUPERGEN, INC. | 2001-01-16 | — | — | US | disclosed |
| EP-1061914-A1 | LIPOIC ACID ANALOGS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6090842-A | REDUCES CONCENTRATION OF OXYGEN IN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000025758-A1 | ORAL ADMINISTRATION OF ADENOSINE ANALOGS | SUPERGEN, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999045922-A1 | LIPOIC ACID ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5728735-A | Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1998-03-17 | — | — | US | disclosed |
| US-5691379-A | Dihydrolipoic acid as an ophthalmological agent to suppress intolerance reactions in the area between implants and living body tissue | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1997-11-25 | — | — | US | disclosed |
| US-5569670-A | ANTIDIABETIC AGENTS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1996-10-29 | — | — | US | disclosed |
| US-5334612-A | Solid, semisolid, solution, suspension or emulsion dosage unit | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-08-02 | — | — | US | disclosed |
| US-5290769-A | Applying compositions for skin disorders | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-03-01 | — | — | US | disclosed |
| US-5284861-A | Blended with deprenyl and biperiden; muscle relaxant | ASTA MEDICA AG (DE) | 1994-02-08 | — | — | US | disclosed |
| US-5271946-A | Controlled release azelastine-containing pharmaceutical compositions | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1993-12-21 | — | — | US | disclosed |
| US-5162346-A | And associated dieeases such as neuralgia, arthritis, headaches, post-operative disability, parkinson*s disorder | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1992-11-10 | — | — | US | disclosed |
| US-5110814-A | Antiinflammatory agents; ulcerative colitis | ASTA PHARMA AG (DE) | 1992-05-05 | — | — | US | disclosed |
| US-5084481-A | 6,8-dimercaptooctanoic acid and salts for rheumatic diseases | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1992-01-28 | — | — | US | disclosed |
| US-5068233-A | For treatment of asthma, antiallergens or antihistamines | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| US-5068233-A | For treatment of asthma, antiallergens or antihistamines | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020330-A1 | Compositions comprising azelastine and methods of use thereof | TAS2R5, TAS2R31, TAS2R13 | TSHR 1329/4885CYP3A4 2757/4885TDP1 4120/4885 |
| US-20010039292-A1 | Lipoic acid analogs | ALOX5, ALOX15, ACSL5 | TSHR 1044/4885CYP3A4 1835/4885TDP1 3829/4885 |
| US-11471413-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | CHRM5, CHRM3, CHRNA5 | TSHR 70/4885CYP3A4 2194/4885TDP1 2858/4885 |
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | TSHR 2290/4885CYP3A4 3164/4885TDP1 219/4885 |
| US-20210401845-A1 | METHODS AND COMPOSITIONS FOR KRAS INHIBITORS | KRAS, NRAS, DHODH | TSHR 4614/4885CYP3A4 3278/4885TDP1 953/4885 |
| US-11312686-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | DHODH, DLD, DPYD | TSHR 3492/4885CYP3A4 69/4885TDP1 563/4885 |
| US-20230124492-A1 | COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE ANALOGS AS INHIBITORS OF KRAS | KRAS, NRAS, TP53 | TSHR 4443/4885CYP3A4 4059/4885TDP1 855/4885 |
| US-11896644-B2 | Inhibition of beta-arrestin oligomerization in tauopathy | ARRB1, SQSTM1, ADRM1 | TSHR 3109/4885CYP3A4 3765/4885TDP1 115/4885 |
| US-20230116783-A1 | INHIBITION OF BETA-ARRESTIN OLIGOMERIZATION IN TAUOPATHY | ARRB1, SQSTM1, ADRM1 | TSHR 3109/4885CYP3A4 3765/4885TDP1 115/4885 |
| US-20210300928-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | AHR, HCCS, HMBS | TSHR 3264/4885CYP3A4 37/4885TDP1 1103/4885 |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | TYMP, HBZ, CDA | TSHR 2307/4885CYP3A4 3164/4885TDP1 223/4885 |
| US-20210198657-A1 | METHODS AND COMPOSITIONS OF CHEMICALLY MODIFIED PHAGE LIBRARIES | CLTB, PTMS, RNPEP | TSHR 1565/4885CYP3A4 3834/4885TDP1 2559/4885 |
| US-10064817-B2 | Compositions comprising azelastine and methods of use thereof | TAS2R5, TAS2R31, TAS2R40 | TSHR 1179/4885CYP3A4 3029/4885TDP1 4077/4885 |
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | CACNA1G, CACNA1I, CACNG2 | TSHR 3306/4885CYP3A4 2934/4885TDP1 1574/4885 |
| US-20230285442-A1 | USE OF OLIGOCHITOSANS AND DERIVATIVES THEREOF FOR NEUTRALIZING VIRAL AGENTS | LGMN, SARS1, OSTC | TSHR 4410/4885CYP3A4 3782/4885TDP1 1373/4885 |
| US-10925832-B2 | Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation | CHRM5, CHRM3, CHRNA5 | TSHR 52/4885CYP3A4 1646/4885TDP1 2737/4885 |
| US-11957682-B2 | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | VCL, HDLBP, VHL | TSHR 4550/4885CYP3A4 3184/4885TDP1 2008/4885 |
| US-11564885-B2 | Centanafadine pharmaceutical formulations, and methods of making and using same | LIPA, ADRA2A, ADRA2C | TSHR 3076/4885CYP3A4 614/4885TDP1 3760/4885 |
| US-20060110331-A1 | Compositions comprising azelastine and methods of use thereof | TAS2R5, TAS2R31, TAS2R13 | TSHR 1329/4885CYP3A4 2757/4885TDP1 4120/4885 |
| US-20240182471-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | AHR, HCCS, HMBS | TSHR 3264/4885CYP3A4 37/4885TDP1 1103/4885 |
| US-20210154146-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | CHRM5, CHRM3, CHRNA5 | TSHR 70/4885CYP3A4 2194/4885TDP1 2858/4885 |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | TSHR 4741/4885CYP3A4 1206/4885TDP1 698/4885 |
| US-20230104529-A1 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | LIPA, ADRA2A, ADRA2C | TSHR 3076/4885CYP3A4 614/4885TDP1 3760/4885 |
| US-20230365521-A1 | COMPOUNDS FOR INCREASING THE NICOTINAMIDE ADENINE DINUCLEOTIDE IN A SUBJECT AND METHODS OF USE THEREOF | NNT, NNMT, SIRT1 | TSHR 4730/4885CYP3A4 2167/4885TDP1 624/4885 |
| US-20240165030-A1 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | LIPA, ADRA2A, ADRA2C | TSHR 3076/4885CYP3A4 614/4885TDP1 3760/4885 |
| US-11980690-B2 | Centanafadine pharmaceutical formulations, and methods of making and using same | LIPA, ADRA2A, ADRA2C | TSHR 3076/4885CYP3A4 614/4885TDP1 3760/4885 |
| US-20210177762-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | CHRM5, CHRM3, CHRNA5 | TSHR 70/4885CYP3A4 2194/4885TDP1 2858/4885 |
| US-20210023060-A1 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | ITGB3, ITGB2, ITGAM | TSHR 1894/4885CYP3A4 490/4885TDP1 1180/4885 |
| US-20220274948-A1 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | CRBN, GSPT1, PRSS12 | TSHR 2046/4885CYP3A4 4373/4885TDP1 1423/4885 |
| US-20230103257-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3 | STAT3, STAT1, JAK2 | TSHR 3032/4885CYP3A4 2790/4885TDP1 894/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | TSHR 2216/4885CYP3A4 4802/4885TDP1 792/4885 |
| US-10828312-B2 | Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders | HMGCR, LCAT, MAPT | TSHR 4333/4885CYP3A4 2432/4885TDP1 1146/4885 |
| US-20210030770-A1 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | HMGCR, LCAT, MAPT | TSHR 4333/4885CYP3A4 2432/4885TDP1 1146/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | TSHR 3836/4885CYP3A4 3026/4885TDP1 1921/4885 |
| US-20230149338-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | CRAT, OPRK1, OPRD1 | TSHR 3138/4885CYP3A4 1009/4885TDP1 3233/4885 |
| US-11912704-B2 | Methods and compositions for substituted arylcycloheptane analogs | AHR, HCCS, HMBS | TSHR 3264/4885CYP3A4 37/4885TDP1 1103/4885 |
| US-20230138583-A1 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | ITGB3, ITGB2, ITGAM | TSHR 1894/4885CYP3A4 490/4885TDP1 1180/4885 |
| US-20230109418-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DDO, DLD | TSHR 4460/4885CYP3A4 432/4885TDP1 831/4885 |
| US-10933020-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | CHRM5, CHRM3, CHRNA5 | TSHR 72/4885CYP3A4 2181/4885TDP1 2831/4885 |
| US-20240018108-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, FAH | TSHR 3289/4885CYP3A4 86/4885TDP1 659/4885 |
| US-20200101018-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | CHRM5, CHRM3, CHRNA5 | TSHR 70/4885CYP3A4 2194/4885TDP1 2858/4885 |
| US-20230181746-A1 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | HDAC3, HDAC1, HDAC5 | TSHR 1503/4885CYP3A4 1437/4885TDP1 1119/4885 |
| US-20200289438-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | HDAC5, HDAC1, HDAC7 | TSHR 3472/4885CYP3A4 3202/4885TDP1 3559/4885 |
| US-20210145804-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | CHRM5, CHRNA5, GPR35 | TSHR 23/4885CYP3A4 1602/4885TDP1 2406/4885 |
| US-20230158030-A1 | METHODS AND COMPOSITION FOR TREATMENT OF COVID-19 ILLNESS REQUIRING HOSPITALIZATION | IL15, IL6, IL2 | TSHR 1567/4885CYP3A4 1458/4885TDP1 3335/4885 |
| US-20220064119-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, DPYD | TSHR 3435/4885CYP3A4 74/4885TDP1 592/4885 |
| US-20210253531-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, DPYD | TSHR 3492/4885CYP3A4 69/4885TDP1 563/4885 |
| US-11141418-B1 | Methods and compositions for KRAS inhibitors | KRAS, NRAS, DHODH | TSHR 4614/4885CYP3A4 3278/4885TDP1 953/4885 |
| US-20100152147-A1 | Compositions Comprising Azelastine and Methods of Use Thereof | TAS2R5, HRH2, IL5 | TSHR 1112/4885CYP3A4 2476/4885TDP1 3925/4885 |
| US-20240140912-A1 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | SYMPK, TXK, HYPK | TSHR 4403/4885CYP3A4 311/4885TDP1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.